Citadel Advisors
RCKT icon

Citadel Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Citadel Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$241K Buy
67,300
+38,700
+135% +$154K ﹤0.01% 10990
2025
Q4 		$100K Sell
28,600
-50,100
-64% -$172K ﹤0.01% 11639
2025
Q3 		$257K Sell
78,700
-26,300
-25% -$82.8K ﹤0.01% 10708
2025
Q2 		$257K Buy
105,000
+37,300
+55% +$189K ﹤0.01% 10145
2025
Q1 		$452K Sell
67,700
-600
-0.9% -$5.93K ﹤0.01% 8699
2024
Q4 		$859K Buy
68,300
+49,700
+267% +$748K ﹤0.01% 7373
2024
Q3 		$344K Sell
18,600
-7,300
-28% -$150K ﹤0.01% 9044
2024
Q2 		$558K Buy
25,900
+13,200
+104% +$303K ﹤0.01% 7835
2024
Q1 		$342K Sell
12,700
-11,400
-47% -$324K ﹤0.01% 9193
2023
Q4 		$722K Buy
24,100
+3,900
+19% +$86.1K ﹤0.01% 7324
2023
Q3 		$414K Buy
20,200
+14,200
+237% +$258K ﹤0.01% 8488
2023
Q2 		$119K Sell
6,000
-4,700
-44% -$95K ﹤0.01% 10667
2023
Q1 		$183K Sell
10,700
-7,300
-41% -$143K ﹤0.01% 10326
2022
Q4 		$352K Buy
+18,000
New +$331K ﹤0.01% 8969
2021
Q3 		– Sell
-71,500
Closed -$3.17M – 14499
2021
Q2 		$3.17M Sell
71,500
-2,600
-4% -$113K ﹤0.01% 5465
2021
Q1 		$3.29M Sell
74,100
-500
-0.7% -$27.5K ﹤0.01% 5221
2020
Q4 		$4.09M Buy
+74,600
New +$2.72M ﹤0.01% 4015
2020
Q2 		– Sell
-19,800
Closed -$276K – 10376
2020
Q1 		$276K Buy
+19,800
New +$392K ﹤0.01% 7483
2019
Q2 		– Sell
-13,800
Closed -$242K – 9731
2019
Q1 		$242K Buy
13,800
+2,400
+21% +$37.9K ﹤0.01% 7922
2018
Q4 		$169K Sell
11,400
-1,700
-13% -$28.2K ﹤0.01% 7986
2018
Q3 		$323K Buy
+13,100
New +$284K ﹤0.01% 7446
2017
Q3 		– Sell
-4,175
Closed -$32K – 7942
2017
Q2 		$32K Sell
4,175
-1,500
-26% -$11.2K ﹤0.01% 7193
2017
Q1 		$45K Sell
5,675
-725
-11% -$4.88K ﹤0.01% 7065
2016
Q4 		$156K Buy
+6,400
New +$183K ﹤0.01% 6484

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's RCKT Position: Q1 2026 in Review

Citadel Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 1,299,991 shares — an estimated $5.17M sold.

Citadel Advisors first reported a position in RCKT in Q3 2015 and held it in 39 quarters. The position peaked at $73.7M in Q4 2023. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Citadel Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,299,991 Rocket Pharmaceuticals shares in Q1 2026, an estimated $5.17M.
  • Citadel Advisors first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 39 quarters.
  • Citadel Advisors's Rocket Pharmaceuticals position peaked at $73.7M in Q4 2023.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.